Understanding Neoadjuvant Trials In High Risk Melanoma
Let's dive into the details surrounding Neoadjuvant Trials In High Risk Melanoma. Panelists Robert H. I. Andtbacka, MD, CM; Georgina Long, MD; and Michael A. Davies, MD, PhD, discuss
Key Takeaways about Neoadjuvant Trials In High Risk Melanoma
- Presentation given by Roda Amaria, MD, as part of the AIM
- Katy Tsai, MD Assistant Professor Hematology and Oncology University of California, San Francisco
- Jason J. Luke, MD, FACP, University of Pittsburgh, Pittsburgh, PA, summarises the KEYNOTE-716
- Omid Hamid, MD, The Angeles Clinic and Research Institute, Los Angeles, CA, discusses the role of
- Dr Tarhini talks to ecancer
Detailed Analysis of Neoadjuvant Trials In High Risk Melanoma
Dr Sapna Patel speaks to ecancer about the SWOG S1801 Rodabe N. Amaria, MD from the University of Texas MD Anderson Cancer Center, Houston, TX summarizes results on a recent ... Eva Muñoz Couselo, MD, PhD, Vall d'Hebrón Hospital, Barcelona, Spain, discusses adjuvant and
In these insightful interviews, Dr Teresa Amaral, Prof. Piotr Rutkowski and Dr Tina Hieken, three renowned experts in
That wraps up our extensive overview of Neoadjuvant Trials In High Risk Melanoma.
